Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Non-cash Items (2017 - 2025)

Historic Non-cash Items for Dianthus Therapeutics (DNTH) over the last 6 years, with Q3 2025 value amounting to $126.2 million.

  • Dianthus Therapeutics' Non-cash Items rose 998394.77% to $126.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $126.2 million, marking a year-over-year increase of 998394.77%. This contributed to the annual value of $1.5 million for FY2024, which is 12921.05% up from last year.
  • According to the latest figures from Q3 2025, Dianthus Therapeutics' Non-cash Items is $126.2 million, which was up 998394.77% from $15.5 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Non-cash Items registered a high of $126.2 million during Q3 2025, and its lowest value of $699237.0 during Q3 2023.
  • Moreover, its 4-year median value for Non-cash Items was $1.8 million (2022), whereas its average is $20.4 million.
  • Data for Dianthus Therapeutics' Non-cash Items shows a peak YoY increase of 998394.77% (in 2025) and a maximum YoY decrease of 9639.55% (in 2025) over the last 5 years.
  • Dianthus Therapeutics' Non-cash Items (Quarter) stood at $1.7 million in 2022, then surged by 87.12% to $3.2 million in 2023, then crashed by 53.12% to $1.5 million in 2024, then skyrocketed by 8364.9% to $126.2 million in 2025.
  • Its Non-cash Items was $126.2 million in Q3 2025, compared to $15.5 million in Q2 2025 and $1.8 million in Q1 2025.